GlaxoSmithKline (NYSE: GSK) has big plans to bring new life its product suite.
In London on Monday, GSK executives laid out an aggressive agenda to investors and analysts – 14 drug candidates to pivotal clinical trial over next two years.
Among those are products that could ”change the way cancer and heart disease are treated,” Reuters reported.
However, GSK Chief Executive Officer Andrew Witty’s team at the drug giant aren’t focusing on so-called blockbusters as in years past, Reuters noted.
GSK is “now developing a broader range of drugs than in the past, as it moves away from the industry’s traditional focus on blockbusters,” Reuters reported.
A “handful have the potential to become multibillion-dollar-a-year sellers,” the wire service added.
“We feel very comfortable, particularly through 2013 and into 2014, that we can manage both with a broadly flat R&D budget and also without significant increases in our commercial organization,” Reuters quoted Witty as saying.
Phase 3 clinical trials in 2013 and 2014 are likely to include heart drug candidate darapladib and therapeutic cancer vaccine MAGE-A3, Reuters noted.
GSK operates its North American headquarters in RTP.
[GSK ARCHIVE: Check out 10 years of GSK stories as reported in WRAL Tech Wire.]
